Malaysia-based Duopharma Biotech Berhad has secured a government contract valued at approximately RM65.08 million (€14.08 million) to supply recombinant human insulin formulations to the Ministry of Health, according to Business Today Malaysia.

The pharmaceutical group said its wholly owned subsidiary Duopharma Marketing, together with manufacturer Biocon Sdn Bhd, had received and accepted a Letter of Award from the government on 16 February 2026. Under the agreement, Biocon will manufacture the insulin products whilst Duopharma Marketing will act as the appointed distributor responsible for delivering the products to the Ministry of Health.

The contract, awarded via direct negotiation, will remain in force until 15 May 2026. The arrangement reflects the continued partnership between Duopharma and Biocon in supplying insulin products to Malaysia's healthcare system, supporting the country's diabetes management programmes.

Biocon Sdn Bhd, a subsidiary of India-based Biocon Biologics, operates one of Asia's largest integrated insulin manufacturing facilities located in BioXcell biotechnology park in Iskandar Puteri, Johor. The facility, built with an investment exceeding $600 million (€509 million), manufactures recombinant human insulin and insulin analogues for both domestic and global markets.

The manufacturing site has received regulatory approvals from several international agencies, including Malaysia's National Pharmaceutical Regulatory Agency, Ireland's Health Products Regulatory Authority, and the US Food and Drug Administration. These certifications enable Biocon to serve multiple markets whilst maintaining compliance with stringent international quality standards.

Malaysia faces a significant diabetes burden, with insulin supply contracts playing a critical role in ensuring continuity of care for patients requiring insulin therapy. The direct negotiation process allows the Ministry of Health to secure essential medicines efficiently whilst maintaining competitive pricing structures.

Read more about Malaysia's pharmaceutical procurement strategy and insulin supply chain in the full report.Duopharma